Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Gonorrhea Market Outlook

Thelansis’s “Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Gonorrhea Overview

Neisseria gonorrhea is an obligate human pathogen primarily transmitted through sexual contact. It infects humans exclusively and commonly causes urethritis in men and cervicitis in women. As an obligate pathogen, N. gonorrhea relies on manifesting disease to facilitate transmission between hosts. It cannot survive outside of a host and must infect a host. The infection process of N. gonorrhea begins with the adherence of gonococci to epithelial cells, followed by local invasion of these cells. Adhesion is facilitated by multiple surface proteins, including pili, hair-like appendages covering the bacterial surface. Pili allow the bacteria to attach to epithelial cells from a distance and promote cellular invasion. Additionally, pili provide motility and protection to the bacteria. Other surface proteins involved in cellular attachment include Opa (opacity-associated proteins) and LOS (lipooligosaccharide), which can attach to sperm cells and potentially contribute to transmission from infected males to uninfected sexual partners. Symptoms of gonorrhea may include green or yellow discharge from the penis, pain or burning sensation during urination, discomfort and swelling of the testicles (in men), increased vaginal discharge, lower abdominal pain (particularly during sex), and bleeding between periods or after sex. In routine settings, the diagnosis of gonorrhea can be verified quickly through direct microscopy of urethral or cervical smears stained with Gram or methylene blue. Gram staining is more specific than methylene blue staining. Risk factors for N. gonorrhea infection include sexual contact with new or multiple partners, sexual contact with individuals who have concurrent partners or current N. gonorrhea infection, inconsistent condom use with nonmonogamous partners, previous history of N. gonorrhea infection, and engaging in sex for money, drugs, or other items. Gonorrhea has increased over the past 20 years due to antimicrobial resistance. If gonorrhea infections are not detected or appropriately treated, they can lead to serious reproductive health complications in women, such as pelvic inflammatory disease, chronic pelvic pain, infertility, first-trimester abortion, and ectopic pregnancy.

• In the USA, the highest reported cases of gonorrhea were observed in women aged 20 to 24 years (866.9 per 100,000), followed by those aged 15 to 19 years (616.4 per 100,000) and 25 to 29 years (505.3 per 100,000). Among men, the highest reported cases were found in those aged 20 to 24 years (821.5 per 100,000), followed by those aged 25 to 29 years (727.9 per 100,000) and 30 to 34 years (567.6 per 100,000). 

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: